Episode Summary
In this episode, John discusses Our Take on health care news in the first half of April 2019. He covers the Times/ProPublica report on Memorial Sloan Kettering Cancer Center, the proposed merger between Atrium Health and Wake Forest Baptist Health, and other top stories through April 15.
Episode Notes
In this episode, John discusses Our Take on health care news in the first half of April 2019. He covers the Times/ProPublica report on Memorial Sloan Kettering Cancer Center, the proposed merger between Atrium Health and Wake Forest Baptist Health, and other top stories through April 15.
- A new report by The New York Times and ProPublica says leadership at Memorial Sloan Kettering Cancer Center (MSK) “repeatedly violated policies on financial conflicts of interest,” resulting in an environment in which “profits appeared to take precedence over research and patient care.”
- Charlotte, N.C.-based Atrium Health signed a memorandum of understanding with Winston Salem, N.C.-based Wake Forest University and Wake Forest Baptist Health to create a “transformative academic health care system.” The organizations said they have entered into a period of exclusive negotiations to agree on terms, and intend to arrive at a final agreement later this year.
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes
Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports
Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations
Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.
